Facebook Instagram Youtube
Speak to our experts

Stem Cell Therapy for Heart Disease and Post-myocardial infarction (MI)

At the Stem Cells Transplant Institute in Costa Rica, our stem cell therapy for cardiovascular conditions helps reduce inflammation, support heart function, and promote recovery after heart damage.

Request a consultation
Learn our protocol
Reviewed: 19 Apr 2026

What is heart disease & post-MI recovery?

Cardiovascular disease (CVD) is a broad term for conditions affecting the heart and blood vessels. Common forms include coronary artery disease (CAD), heart failure, cardiomyopathies, valvular heart disease, arrhythmias, and diseases of the aorta and peripheral vessels. 

According to the World Heart Federation (2023), more than 18 million people die each year from cardiovascular disease, and many more live with long-term limitations after major cardiac events.

A myocardial infarction (MI), commonly known as a heart attack, is a medical emergency that occurs when blood flow to part of the heart muscle is suddenly blocked, leading to tissue injury. CAD is the most common underlying cause.

After an MI, the heart may heal by forming scar tissue rather than fully regenerating muscle. This can contribute to reduced pumping function, fatigue, decreased exercise tolerance, and an increased risk of heart failure over time.

request a free consultation

Why Seek Stem Cell Therapy for Heart Disease in Costa Rica?

Stem Cells Transplant Institute in San José, Costa Rica, provides regenerative medicine programs for patients with heart disease who are clinically stable but continue to experience functional limitations related to coronary artery disease or prior myocardial infarction. Our protocols are a complement to existing cardiology care, within a facility equipped for continuous hemodynamic monitoring.

For patients from the United States, Canada, and Europe who experience reduced exercise tolerance or impaired cardiac function despite optimized medical management, the institute offers physician-supervised mesenchymal stem cell (MSC) protocols within a structured clinical environment. San José is accessible via direct flights from most major North American cities, allowing for short-duration treatment visits.

Every cardiac protocol is built on a pre-travel review of the patient’s current hemodynamic status and medication regimen. When appropriate, coordination with the patient’s treating cardiologist is incorporated into the planning process. Post-treatment follow-up is conducted at defined intervals, typically at 1, 3, 6, and 12 months, to monitor outcomes, including changes in exercise capacity and overall cardiac function.

Common Characteristics

  • Chest pain or chest pressure
  • Shortness of breath
  • Nausea or indigestion-like discomfort
  • Irregular heartbeat or palpitations
  • Dizziness, lightheadedness, or fainting
  • Swelling of the legs/ankles (fluid retention)
  • Fatigue or reduced exercise tolerance
Evidence-Based Treatment

Why Stem Cell Therapy for Heart Disease & MI Recovery?

MSCs are studied for their ability to support tissue repair primarily through paracrine signaling—the release of bioactive factors that may help create a healthier environment for recovery in damaged or stressed tissue.

Research suggests that mesenchymal stem cells may help: modulate harmful post-MI inflammation, support healthier tissue conditions around injured myocardium, promote microcirculation and microvascular support, support vascular repair processes, reduce oxidative stress signaling, contribute to a more stable functional tissue environment.

Stem cell therapy is intended as a complement to standard cardiology care—not a replacement for medication, lifestyle changes, cardiac rehabilitation, or emergency treatment.

 (Evidence remains preliminary, and ongoing controlled clinical trials are required to confirm the magnitude and consistency of these effects.)

1

Reducing damaging post-MI inflammation

MSCs release immunomodulatory molecules that may help reduce inflammation and may help protect vulnerable heart cells. (Hare et al., 2017)

2

Supporting microvascular repair and blood flow

MSCs communicate with surrounding cells by releasing natural signals that may help support healthy blood vessels and improve the tissue environment over time.(Quijada et al., 2020)

3

Protecting heart muscle cells (cardiomyocytes)

MSCs secrete protective factors that may help existing heart cells tolerate stress and support cellular function.  (Gonzalez-King et al., 2017)

4

Improving tissue remodeling after injury

Through their natural signaling activity, MSCs may help influence healing and scarring processes after injury, supporting a healthier tissue environment as the heart recovers. (Heldman et al., 2014)

Icono minimalista de un cerebro humano de color púrpura que destaca la división entre los dos hemisferios cerebrales sobre un fondo negro sólido.
request a free consultation

Expected Benefits & Clinical Observations

Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:

Left ventricular ejection fraction (LVEF) improvement (absolute points or relative change as defined by each study)
8-15%
Exercise tolerance
20-30%
Reduction in inflammatory markers
25-40%
Quality of life scores (instrument-dependent)
30-40%

*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy for Heart Disease and MI recovery remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.

Timeline of Reported Improvements

Published studies and patient-reported outcomes suggest that improvements after mesenchymal stem cell (MSC) therapy for Heart Disease may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.

1-3 months
Some patients report improved stamina and reduced symptom burden when combined with standard cardiology care and rehabilitation.
3-6 months
Some studies describe gradual changes in functional capacity and exercise tolerance
6-12 months
Longer-term follow-up in selected reports may describe remodeling-related changes; findings are variable and not consistent across all studies.

*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in Heart disease remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.

Safety note: New or worsening chest pain, shortness of breath, fainting, or concerning symptoms require urgent medical evaluation.

request a free consultation

Patient Stories & Testimonials

Frequently Asked Questions

No. Stem cell therapy is not a cure for heart disease or heart attacks. It is considered an adjunct, experimental approach that may help support a healthier tissue environment and inflammation modulation in some patients. Standard cardiology care remains essential, including medications, lifestyle changes, cardiac rehabilitation, and emergency evaluation when needed.

We use mesenchymal stem cells (MSCs), typically umbilical cord–derived MSCs. MSCs are widely studied because they have low immunogenicity and immunomodulatory properties, and they can release signaling factors that may support tissue repair processes.

Your cardiologist must confirm medical stability first. In general, treatment is not performed immediately after an MI.  Many patients are evaluated after the initial healing period (typically at least 6–8 weeks) and, depending on recovery and stability, may undergo therapy several months after the event as part of an overall cardiology and rehabilitation plan.

During treatment:

  • You will receive mesenchymal stem cells either through a simple intravenous (IV) infusion or, in selected cases, through catheter-based intracoronary administration in a specialized clinical setting. The route is individualized based on your diagnosis, cardiac stability, and your treating team’s assessment.
  •  Depending on your case, the clinic may discuss additional supportive therapies (such as antioxidant therapy with vitamin C and glutathione, ozone therapy, and platelet-rich plasma (PRP)). These are optional, are not required for everyone, and are selected on a case-by-case basis. Results vary, and no outcome can be guaranteed.

 

After treatment:

  • Many patients can resume light activities within 24 hours, depending on their condition and medical guidance.
  • You will have scheduled follow-ups at 3 and 6 months to track progress.
  • Improvements, when they occur, usually appear gradually over weeks to months.
contact an expert today

Key Research Studies

Transendocardial Mesenchymal Stem Cells for Ischemic Cardiomyopathy (TAC-HFT Trial)

JAMA • 2014

Randomized clinical trial evaluating mesenchymal stem cells and bone marrow mononuclear cells showing improved cardiac function and safety outcomes in ischemic cardiomyopathy.

View published study

Mesenchymal Stem Cell Therapy After Myocardial Infarction

European Heart Journal • 2017

Randomized trial demonstrating cardiopoietic and anti-inflammatory effects of mesenchymal stem cell therapy following myocardial infarction.

View published study

Cardiac Regeneration and Stem Cell Therapy

Current Opinion in Organ Transplantation • 2008

Scientific review discussing regenerative mechanisms and therapeutic potential of stem cell therapy for cardiac repair.

View published study

Umbilical Cord MSC Extracellular Vesicles Protect Against Heart Failure

Frontiers in Bioengineering and Biotechnology • 2021

Experimental study showing that extracellular vesicles derived from umbilical cord MSCs may protect cardiac tissue and improve heart failure outcomes.

View published study
info
Location

San José, Costa Rica

Contact Us

info@stemcellstransplantinstitute.com

Call Center

+1 888 785-4170

APPLY TODAY